Pure Global
NCT06404905

Clinical Trial of BT02 in Patients With Advanced Solid Tumors

A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Antitumor Activity of BT02 in Patients With Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Advanced Solid Tumor
Drug/Device/Intervention
BT02 monoclonal antibody injection
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Location
Beijing, China
Timeline & enrollment
Phase
Phase 1
Start date
Jan 24, 2024
End date
Dec 31, 2024
Enrollment
60 participants
Primary outcome

Dose Limiting Toxicity,Incidence and severity of adverse events (AEs) and serious adverse events (SAEs),Maximum tolerated dose

Summary

A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability,
 Pharmacokinetics, Immunogenicity and Preliminary Antitumor Activity of BT02 in Patients with
 Advanced Solid Tumors

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm: PrepuceMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissue
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06404905
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06404905 through Pure Global AI's free database. This Phase 1 trial is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and is currently Recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.